Candesartan reduces oxidative stress and inflammation in patients with essential hypertension

Hypertension Research

Volumn 26, Issue 9, 2003, Pages 691-697

  Dohi, Yasuaki ^c   Ohashi, Masuo ^c   Sugiyama, Masaya ^c   Takase, Hiroyuki ^a   Sato, Koichi ^b   Ueda, Ryuzo ^c  

^a Enshu General Hospital   (Japan)

^b Johoku Hospital   (Japan)

^c NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Angiotensin II type 1 receptor; C reactive protein; Hypertension; Inflammation; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 ISOPROSTAGLANDIN F2 ALPHA; ANGIOTENSIN 1 RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG ACTIVITY; DRUG INFORMATION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPOTHESIS; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TISSUE INJURY; URINE LEVEL;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; C-REACTIVE PROTEIN; DINOPROST; FEMALE; HUMANS; HYPERTENSION; IMMUNOENZYME TECHNIQUES; INFLAMMATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; TETRAZOLES; TREATMENT OUTCOME;

EID: 0141961908     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.691     Document Type: Article

References (41)

1. Rajagopalan S, Kurz S, Munzel T, et al: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
2. phox mRNA expression and NADH/NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45-51.
3. Schnackenberg CG, Wilcox CS: Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin F2α. Hypertension 1999; 33: 424-428.
4. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
5. Lerman LO, Nath KA, Rodriguez-Porcel M, et al: Increased oxidative stress in experimental renovascular hypertension. Hypertension 2001; 37: 541-546.
6. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A: Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97: 2222-2229.
7. Touyz RM, Schiffrin EL: Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 2001; 19: 1245-1254.
8. Yasunari K, Maeda K, Nakamura M, Yoshikawa J: Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension 2002; 39: 777-780.
9. Alexander RW: Theodore Cooper Memorial Lecture: hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995; 25: 155-161.
10. Romeo JC, Reckelhoff JF: State-of-the-art lecture: role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34: 943-949.
11. Nickenig G, Harrison DG: The AT1-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002; 105: 393-396.
12. Weiss D, Sorescu D, Taylor WR: Angiotensin II and atherosclerosis. Am J Cardiol 2001; 87 (Suppl): 25C-32C.
13. Brasier AR, Recinos A III, Eledrisi MS: Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257-1266.
14. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
15. Kawazoe T, Kosaka H, Yoneyama H, Hata Y: Acute production of vascular superoxide by angiotensin II but not by catecholamines. J Hypertens 2000; 18: 179-185.
16. Kyaw M, Yoshizumi M, Tsuchiya K, Kirima K, Tamaki T: Antioxidants inhibit JNK and p38 MAPK activation but not ERK 1/2 activation by angiotensin II in rat aortic smooth muscle cells. Hypertens Res 2001; 24: 251-261.
17. Watanabe T, Pakala R, Katagiri T, Benedict CR: Antioxidant N-acetylcysteine inhibits vasoactive agents-potentiated mitogenic effect of mildly oxidized LDL on vascular smooth muscle cells. Hypertens Res 2002; 25: 311-315.
18. Shinomiya K, Fukunaga M, Kiyomoto H, et al: A role of oxidative stress-generated eicosanoid in the progression of arteriosclerosis in type 2 diabetes mellitus model. Hypertens Res 2002; 25: 91-98.
19. Patel RP, Moellering D, Murphy-Ullrich J, Jo H, Beckman JS, Darley-Usmar VM: Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med 2000; 28: 1780-1794.
20. Luft FC, Mervaala E, Muller DN, et al: Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension 1999; 33: 212-218.
21. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB: Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-κB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 645-651.
22. Usui M, Egashira K, Tomita H, et al: Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000; 101: 305-310.
23. Schiffrin EL, Park JB, Intengan HD, Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-1659.
24. Prasad A, Tupas-Habib T, Schenke WH, et al: Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349-2354.
25. Welch WJ, Wilcox CS: AT1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR. Kidney Int 2001; 59: 1257-1263.
26. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJD: A series of prostaglandin F2α-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990; 87: 9383-9387.
27. Delanty N, Reilly M, Pratico D, FitzGerald DJ, Lawson JA, FitzGerald GA: 8-Epi PGF2α: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br J Clin Pharmacol 1996; 42: 15-19.
28. Pratico D, Lawson JA, FitzGerald GA: Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin FF2α. J Biol Chem 1995; 270: 9800-9808.
29. Simic MG: Urinary biomarkers and the rate of DNA damage in carcinogenesis and anticarcinogenesis. Mutat Res 1992; 267: 277-290.
30. Perloff D, Grim C, Flack J, et al: Human blood pressure determination by sphygmomanometry. Circulation 1993; 88: 2460-2470.
31. Rifai N, Tracy RP, Ridker PM: Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136-2141.
32. Walsh SW, Vaughan JE, Wang Y, Roberts LJ II: Placental isoprostane is significantly increased in preeclampsia. FASEB J 2000; 14; 1289-1296.
33. Leinonen J, Lehtimäki T, Toyokuni S, et al: New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus. FEBS Lett 1997; 417: 150-152.
34. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Infammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
35. Liuzzo G, Biasucci LM, Gallimore JR, et al: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417-424.
36. Kuller LH, Tracy RP, Shaten J, Meilahn EN, for the MRFIT Research Group: Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996; 144: 537-547.
37. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-428.
38. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
39. Aizawa T, Ishizaka N, Usui S, Ohashi N, Ohno M, Nagai R: Angiotensin II and catecholamines increase plasma levels of 8-epi-prostaglandin F2α with different pressor dependencies in rats. Hypertension 2002; 39: 149-154.
40. Wassmann S, Hilgers S, Laufs U, Bohm M, Nickenig G: Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002; 22: 1208-1212.
41. Bautista L, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI: Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 857-861.